<DOC>
	<DOC>NCT00613652</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies</brief_summary>
	<brief_title>A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients</brief_title>
	<detailed_description />
	<criteria>Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments. Patients who usually have mild symptoms capable of walking and light and sedentary work. Patients who can stay in hospital at least during 4 weeks. Patients who have received treatment with anticancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anticancer agent is mitomycin. Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function. Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>solid tumors</keyword>
	<keyword>solid malignancies</keyword>
</DOC>